PERCEPTIVE ADVISORS LLC — 13F Holdings & Portfolio
CIK 1224962 · latest 13F-HR filed 2026-08-14
PERCEPTIVE ADVISORS LLC manages $6.66B in 13F-reported U.S. long-equity assets across 109 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PRAX (10.23%), SYRE (5.76%), CELC (5.02%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 23 new positions and exited 13; 46 existing positions rose in reported value and 23 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 48.9%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Jul 13, 2026.
10TH FLR
NEW YORK, NY 10003
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| COHN, SHMUEL, MORDECHAI Control | CHIEF FINANCIAL OFFICER since Jul 2026 | Less than 5% | Individual |
| EDELMAN, JOSEPH, ERIC Control | CHIEF EXECUTIVE OFFICER AND PORTFOLIO MANAGER since Dec 2000 | 75% or more | Individual |
| MANNIX, JAMES, HENRY Control | CHIEF OPERATING OFFICER since Dec 2006 | Less than 5% | Individual |
| RAKITIN, ALEXANDER, NMN Control | CHIEF COMPLIANCE OFFICER since Oct 2017 | Less than 5% | Individual |
| ROSNER, MARCEL, TREBOUX Control | GENERAL COUNSEL since Feb 2025 | Less than 5% | Individual |
| STONE, ADAM, LEO Control | CHIEF INVESTMENT OFFICER since Dec 2025 | 10–25% | Individual |
Ownership & leadership changes · 5 filings with changes since Mar 30, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedFIERRO, PETER, WILLIAM · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Jul 2007
- ChangedCOHN, SHMUEL, MORDECHAI · title CHIEF FINANCIAL OFFICER - CREDIT & VENTURE → CHIEF FINANCIAL OFFICER
- AddedCOHN, SHMUEL, MORDECHAI · CHIEF FINANCIAL OFFICER - CREDIT & VENTURE · Less than 5% · control person
- AddedSTONE, ADAM, LEO · CHIEF INVESTMENT OFFICER · 10–25% · control person
- AddedROSNER, MARCEL, TREBOUX · GENERAL COUNSEL · Less than 5% · control person
- AddedRAKITIN, ALEXANDER, NMN · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedMANNIX, JAMES, HENRY · title CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER
- ChangedEDELMAN, JOSEPH, ERIC · title CEO → CHIEF EXECUTIVE OFFICER AND PORTFOLIO MANAGER
- ChangedFIERRO, PETER, WILLIAM · title CFO → CHIEF FINANCIAL OFFICER
- ChangedMANNIX, JAMES, HENRY · title CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
- ListedEDELMAN, JOSEPH, ERIC · CEO · 75% or more · control person
- ListedFIERRO, PETER, WILLIAM · CFO · Less than 5% · control person
- ListedMANNIX, JAMES, HENRY · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- SPYRE THERAPEUTICS INC$192.7M +101.0%
- RELAY THERAPEUTICS INC$166.9M +172.0%
- TRAVERE THERAPEUTICS INC$90.1M +73.2%
- TANGO THERAPEUTICS INC$88.7M +524.4%
- RHYTHM PHARMACEUTICALS INC$80.7M +39.1%
Top Trims
- NAUTILUS BIOTECHNOLOGY INC-$27.1M -55.5%
- ABIVAX SA-$26.8M -73.1%
- DYNE THERAPEUTICS INC-$24.9M -29.4%
- CELCUITY INC-$22.4M -6.3%
- GUARDANT HEALTH INC-$21.5M -77.6%
New Positions
- ASCENDIS PHARMA A/S$310.4M
- KARDIGAN INC$195.6M
- AVALYN PHARMACEUTICALS INC$88.1M
- BIOGEN INC$59.7M
- UNITEDHEALTH GROUP INC$48.5M
Exited Positions
- ASCENDIS PHARMA A/S$350.3M
- CENTESSA PHARMACEUTICALS PLC$208.9M
- ENGENE HOLDINGS INC$39.7M
- DAY ONE BIOPHARMACEUTICALS I$37.6M
- BRIGHT MINDS BIOSCIENCES INC$27.5M
PERCEPTIVE ADVISORS LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $681.6M | 10.23% | 2,035,986 | SH |
| 2 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $383.5M | 5.76% | 4,319,496 | SH |
| 3 | CELCUITY INC | CELC | 15102K100 | $334.5M | 5.02% | 3,197,200 | SH |
| 4 | ASCENDIS PHARMA A/S | ASND | K08588103 | $310.4M | 4.66% | 1,163,721 | SH |
| 5 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $287.2M | 4.31% | 2,586,295 | SH |
| 6 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $286.1M | 4.30% | 8,085,461 | SH |
| 7 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $263.9M | 3.96% | 14,106,187 | SH |
| 8 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $213.2M | 3.20% | 3,752,574 | SH |
| 9 | KARDIGAN INC | KARD | 485925101 | $195.6M | 2.94% | 8,200,662 | SH |
| 10 | NUVALENT INC | NUVL | 670703107 | $195.2M | 2.93% | 1,580,505 | SH |
| 11 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $177.7M | 2.67% | 4,373,974 | SH |
| 12 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $173.6M | 2.61% | 1,308,113 | SH |
| 13 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $149.7M | 2.25% | 8,334,882 | SH |
| 14 | MEIRAGTX HLDGS PLC | MGTX | G59665102 | $145.7M | 2.19% | 10,786,658 | SH |
| 15 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $128.0M | 1.92% | 1,345,063 | SH |
| 16 | INHIBRX BIOSCIENCES INC | INBX | 45720N103 | $123.0M | 1.85% | 1,297,763 | SH |
| 17 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $120.4M | 1.81% | 981,879 | SH |
| 18 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $118.9M | 1.79% | 11,906,646 | SH |
| 19 | ZYMEWORKS INC | ZYME | 98985Y108 | $109.3M | 1.64% | 4,182,953 | SH |
| 20 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $105.6M | 1.58% | 3,377,000 | SH |
| 21 | IMMATICS N.V | IMTX | N44445109 | $105.2M | 1.58% | 10,383,456 | SH |
| 22 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $104.8M | 1.57% | 4,320,422 | SH |
| 23 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $103.1M | 1.55% | 10,308,888 | SH |
| 24 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $98.8M | 1.48% | 527,600 | SH |
| 25 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $88.1M | 1.32% | 2,675,296 | SH |
| 26 | MODERNA INC Put | MRNA | 60770K107 | $70.0M | 1.05% | 1,000,000 | SH |
| 27 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $59.7M | 0.90% | 2,689,235 | SH |
| 28 | BIOGEN INC | BIIB | 09062X103 | $59.7M | 0.90% | 276,173 | SH |
| 29 | IMMUNOVANT INC | IMVT | 45258J102 | $52.3M | 0.79% | 1,357,383 | SH |
| 30 | UNITEDHEALTH GROUP INC | UNH | 91324P102 | $48.5M | 0.73% | 116,806 | SH |
| 31 | SPDR SERIES TRUST Put | XBI | 78464A870 | $47.5M | 0.71% | 300,000 | SH |
| 32 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $44.9M | 0.67% | 566,000 | SH |
| 33 | SUTRO BIOPHARMA INC | STRO | 869367201 | $43.3M | 0.65% | 1,304,846 | SH |
| 34 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $42.5M | 0.64% | 1,609,893 | SH |
| 35 | JAZZ PHARMACEUTICALS PLC | JAZZ | G50871105 | $41.0M | 0.61% | 170,000 | SH |
| 36 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $39.9M | 0.60% | 2,667,441 | SH |
| 37 | SIONNA THERAPEUTICS INC | SION | 829401108 | $39.8M | 0.60% | 905,000 | SH |
| 38 | CYTOMX THERAPEUTICS INC. | CTMX | 23284F105 | $39.1M | 0.59% | 10,439,185 | SH |
| 39 | ARTIVION INC | AORT | 228903100 | $39.0M | 0.59% | 1,737,290 | SH |
| 40 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $37.0M | 0.56% | 7,933,491 | SH |
| 41 | CORCEPT THERAPEUTICS INC | CORT | 218352102 | $34.6M | 0.52% | 398,385 | SH |
| 42 | REPLIGEN CORP | RGEN | 759916109 | $33.9M | 0.51% | 248,212 | SH |
| 43 | ANTERIS TECHNOLOGIES GLOBAL | AVR | 03675P102 | $33.7M | 0.51% | 3,425,476 | SH |
| 44 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $32.2M | 0.48% | 773,342 | SH |
| 45 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $31.8M | 0.48% | 1,223,000 | SH |
| 46 | CHARLES RIV LABS INTL INC | CRL | 159864107 | $31.8M | 0.48% | 140,000 | SH |
| 47 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $29.0M | 0.44% | 118,450 | SH |
| 48 | EYEPOINT INC Put | EYPT | 30233G209 | $28.6M | 0.43% | 2,000,000 | SH |
| 49 | DBV TECHNOLOGIES S A | DBVT | 23306J309 | $27.1M | 0.41% | 1,653,350 | SH |
| 50 | IRHYTHM HOLDINGS INC | IRTC | 450056106 | $26.6M | 0.40% | 223,766 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $6.66B | 109 | 0001012975-26-000777 |
| 2026-03-31 | 2026-05-15 | $5.11B | 94 | 0001012975-26-000443 |
| 2026-03-31 | 2026-05-29 | $5.12B | 94 | 0001012975-26-000499 |
| 2025-12-31 | 2026-02-17 | $5.61B | 116 | 0001012975-26-000155 |
| 2025-09-30 | 2025-11-14 | $3.46B | 93 | 0001012975-25-000762 |
NEW YORK, NY 10003